Protara Therapeutics (TARA) Non-Current Deferred Tax Liability (2019 - 2023)
Protara Therapeutics (TARA) posted quarterly Non-Current Deferred Tax Liability of $9.6 million for Q4 2023, up 43786.36% year-over-year from N/an in Q4 2022, and up 43786.36% quarter-over-quarter from -$22000.0 in Q4 2022.
Protara Therapeutics (TARA) Non-Current Deferred Tax Liability (2019 - 2023) Analysis & Trends
Protara Therapeutics (TARA) has reported Non-Current Deferred Tax Liability for 5 consecutive years, with $9.6 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Non-Current Deferred Tax Liability rose 43786.36% year-over-year to $9.6 million; the TTM figure through Dec 2023 stood at $9.6 million (up 43786.36% YoY), while the FY2023 annual figure was $9.6 million, up 43786.36% from the prior year.
- Non-Current Deferred Tax Liability rose to $9.6 million in Q4 2023 per TARA's latest filing, from -$22000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $9.6 million in Q4 2023 and bottomed at -$22000.0 in Q4 2022.
- Historically, Non-Current Deferred Tax Liability has averaged $1.6 million across 5 years, with a median of $355500.0 in 2020.
- Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability plunged 101.42% — and 2023, when it surged 43786.36%.
- Protara Therapeutics' Non-Current Deferred Tax Liability stood at $2000.0 in 2019, then soared by 16000.0% to $322000.0 in 2020, then soared by 381.06% to $1.5 million in 2021, then slumped by 101.42% to -$22000.0 in 2022, then soared by 43786.36% to $9.6 million in 2023.
- Business Quant data shows TARA's Non-Current Deferred Tax Liability at $9.6 million in Q4 2023, -$22000.0 in Q4 2022, and $829000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 9.61 Mn |
| Dec 31, 2023 | 9.61 Mn |
| Dec 31, 2022 | -22,000.00 |
| Dec 31, 2022 | -22,000.00 |
| Sep 30, 2022 | 829,000.00 |
| Sep 30, 2022 | 829,000.00 |
| Dec 31, 2021 | 1.55 Mn |
| Dec 31, 2021 | 1.55 Mn |
| Jun 30, 2021 | 197,000.00 |
| Jun 30, 2021 | 197,000.00 |
| Mar 31, 2021 | 389,000.00 |
| Mar 31, 2021 | 389,000.00 |
| Dec 31, 2020 | 322,000.00 |
| Dec 31, 2020 | 322,000.00 |
| Dec 31, 2019 | 2,000.00 |
| Dec 31, 2019 | 2,000.00 |